These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 21075714

  • 1. Consensus statement on the adherence to Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing Guidelines (CLSI-2010 and CLSI-2010-update) for Enterobacteriaceae in clinical microbiology laboratories in Taiwan.
    Hsueh PR, Ko WC, Wu JJ, Lu JJ, Wang FD, Wu HY, Wu TL, Teng LJ.
    J Microbiol Immunol Infect; 2010 Oct; 43(5):452-5. PubMed ID: 21075714
    [No Abstract] [Full Text] [Related]

  • 2. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.
    Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN, Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute.
    Clin Infect Dis; 2013 May; 56(9):1301-9. PubMed ID: 23334813
    [Abstract] [Full Text] [Related]

  • 3. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.
    Kahlmeter G.
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():169-74. PubMed ID: 18154542
    [Abstract] [Full Text] [Related]

  • 4. New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria.
    Jorgensen JH, Hindler JF.
    Clin Infect Dis; 2007 Jan 15; 44(2):280-6. PubMed ID: 17173232
    [Abstract] [Full Text] [Related]

  • 5. Comparison of disk diffusion, VITEK 2, and broth microdilution antimicrobial susceptibility test results for unusual species of Enterobacteriaceae.
    Stone ND, O'Hara CM, Williams PP, McGowan JE, Tenover FC.
    J Clin Microbiol; 2007 Feb 15; 45(2):340-6. PubMed ID: 17135429
    [Abstract] [Full Text] [Related]

  • 6. Reevaluation of Clinical and Laboratory Standards Institute disk diffusion breakpoints for tetracyclines for testing Enterobacteriaceae.
    Sader HS, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Jones RN.
    J Clin Microbiol; 2007 May 15; 45(5):1640-3. PubMed ID: 17360844
    [Abstract] [Full Text] [Related]

  • 7. Systems approach to improving antimicrobial susceptibility testing in clinical laboratories in the United States.
    Counts JM, Astles JR, Tenover FC, Hindler J.
    J Clin Microbiol; 2007 Jul 15; 45(7):2230-4. PubMed ID: 17522281
    [Abstract] [Full Text] [Related]

  • 8. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends).
    Hsueh PR, Badal RE, Hawser SP, Hoban DJ, Bouchillon SK, Ni Y, Paterson DL, 2008 Asia–Pacific SMART Group.
    Int J Antimicrob Agents; 2010 Nov 15; 36(5):408-14. PubMed ID: 20728316
    [Abstract] [Full Text] [Related]

  • 9. Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.
    Heil EL, Johnson JK.
    J Clin Microbiol; 2016 Apr 15; 54(4):840-4. PubMed ID: 26791363
    [Abstract] [Full Text] [Related]

  • 10. Cefazolin and enterobacteriaceae: rationale for revised susceptibility testing breakpoints.
    Turnidge JD, Subcommittee on Antimicrobial Susceptibility Testing of the Clinical and Laboratory Standards Institute.
    Clin Infect Dis; 2011 Apr 01; 52(7):917-24. PubMed ID: 21427400
    [Abstract] [Full Text] [Related]

  • 11. [Consensus for antimicrobial susceptibility testing for Enterobacteriaceae. Subcommittee on Antimicrobials, SADEBAC (Argentinian Society of Clinical Bacteriology), Argentinian Association of Microbiology].
    Famiglietti A, Quinteros M, Vázquez M, Marín M, Nicola F, Radice M, Galas M, Pasterán F, Bantar C, Casellas JM, Kovensky Pupko J, Couto E, Goldberg M, Lopardo H, Gutkind G, Soloaga R, Subcomisión de Antimicrobianos of the Sociedad Argentina de Bacteriología Clinica (Asociación Argentina de Microbiología).
    Rev Argent Microbiol; 2005 Apr 01; 37(1):57-66. PubMed ID: 15991480
    [Abstract] [Full Text] [Related]

  • 12. [Interpretation of the susceptibility test results in enterobacteria producing 3rd- and 4th-generation cephalosporin- or carbapenem-hydrolyzing beta-lactamases].
    Hrabák J, Zemlicková H, Bergerová T, Urbásková P.
    Epidemiol Mikrobiol Imunol; 2011 Feb 01; 60(1):4-9. PubMed ID: 21542230
    [Abstract] [Full Text] [Related]

  • 13. Correction of a reference to clinical laboratory standards institute interpretive criteria.
    Wikler MA, Ferraro MJ.
    Clin Infect Dis; 2008 Jun 01; 46(11):1798; author reply 1798-9. PubMed ID: 18462124
    [No Abstract] [Full Text] [Related]

  • 14. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR, Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Sep 01; 56(1):57-62. PubMed ID: 16631338
    [Abstract] [Full Text] [Related]

  • 15. [Patterns of susceptibility to antibiotics of Enterobacteriaceae causing intra-abdominal infection in Spain: SMART 2003 study outcomes].
    Baquero F, Cercenado E, Cisterna R, de la Rosa M, García-Rodríguez JA, Gobernado M, Pérez JL, Manchado P, Martín R, Pascual A, Picazo J, Prats G, Rubio C, Snyder TA, Sanz-Rodríguez C.
    Rev Esp Quimioter; 2006 Mar 01; 19(1):51-9. PubMed ID: 16688292
    [Abstract] [Full Text] [Related]

  • 16. Performance of Vitek 2 for antimicrobial susceptibility testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI breakpoints.
    Bobenchik AM, Deak E, Hindler JA, Charlton CL, Humphries RM.
    J Clin Microbiol; 2015 Mar 01; 53(3):816-23. PubMed ID: 25540403
    [Abstract] [Full Text] [Related]

  • 17. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards.
    Humphries RM, Fang FC, Aarestrup FM, Hindler JA.
    Clin Infect Dis; 2012 Oct 01; 55(8):1107-13. PubMed ID: 22752519
    [Abstract] [Full Text] [Related]

  • 18. Towards a rational antimicrobial testing policy in the laboratory.
    Banaji N, Oommen S.
    Indian J Med Microbiol; 2011 Oct 01; 29(3):209-12. PubMed ID: 21860098
    [Abstract] [Full Text] [Related]

  • 19. Do patient data really support the clinical and laboratory standards institute recommendation for lowering third-generation cephalosporin interpretive breakpoints?
    Tamma PD, Powers JH.
    Clin Infect Dis; 2013 Aug 01; 57(4):624-5. PubMed ID: 23658433
    [No Abstract] [Full Text] [Related]

  • 20. Analysis of Potential β-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae.
    Hackel MA, Iaconis JP, Karlowsky JA, Sahm DF.
    J Clin Microbiol; 2018 Apr 01; 56(4):. PubMed ID: 29436424
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.